Clinical trials: Placebo Group
Osteoarthritis, Knee
Bioequivalence Study With Clinical Endpoint for Diclofenac Sodium Topical Gel 1%
A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Three-Arm, Multi-Site Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Topical Gel 1% (Hi-Tech Pharmacal Co., Inc.) With Voltaren® Gel (Diclofenac…
- Trial name
- NCT02913521
- Testing
- Diclofenac Sodium Gel 1%, Voltaren Gel
- Where
- 51 sites in Estonia, Latvia and 4 more
- Volunteers
- 934 people
- Sponsor
- Akorn, Inc.
Multiple Sclerosis
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
The purpose of the study is to show that individuals treated with Fampridine-SR tablets are significantly more likely to have consistent improvements in their walking than those treated with placebo tablets.
- Trial name
- NCT00483652
- Testing
- Fampridine-SR
- Where
- 40 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Acorda Therapeutics
Opioid-induced Constipation
Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation
The purpose of this study is to evaluate the efficacy and safety of naldemedine in the treatment of opioid-induced constipation (OIC) in adults with non-malignant chronic pain who are not using laxatives.
- Trial name
- NCT01965158
- Testing
- Naldemedine
- Where
- 65 sites in United States, Austria and 5 more
- Volunteers
- 547 people
- Sponsor
- Shionogi
Hypercholesterolaemia
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Primary Objectives: To demonstrate the superiority of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) in participants with diabetes treated with insulin and with…
- Trial name
- NCT02585778
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
- Where
- 110 sites in United States, Austria and 8 more
- Volunteers
- 517 people
- Sponsor
- Sanofi
Lumbosacral Radiculopathy
Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain
Efficacy and Safety of ETX 018810 in Subjects with Lumbosacral Radicular Pain
- Trial name
- NCT04778592
- Testing
- ETX-018810
- Where
- 24 sites in United States
- Volunteers
- 149 people
- Sponsor
- Eliem Therapeutics (UK) Ltd.
Obesity
A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes
The purpose of this study is to test the safety and effectiveness of JNJ-28431754 in promoting weight loss in patients who are overweight or obese and who do not have diabetes.
- Trial name
- NCT00650806
- Testing
- Canagliflozin (JNJ-28431754)
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 376 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
This study examined the safety, tolerability, and efficacy of mirabegron (YM178) compared to placebo.
- Trial name
- NCT00410514
- Testing
- Mirabegron
- Where
- 27 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Astellas Pharma Inc
Acute Pain
Bunionectomy Study (0000-063)
We are interested in whether bunionectomy can be used as a model to study the treatment of acute pain. It has been used to study the effect of Non-Steroidal Anti-inflammatory (NSAIDS) medications (such as ibuprofen) and other…
- Trial name
- NCT00601458
- Testing
- pregabalin, naproxen sodium
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics
This multicenter study assessed the effects of 24 weeks of basmisanil treatment on cognition and functioning of stable schizophrenia participants treated with antipsychotics.
- Trial name
- NCT02953639
- Testing
- Basmisanil
- Where
- 37 sites in United States
- Volunteers
- 214 people
- Sponsor
- Hoffmann-La Roche
Proteinuria, Idiopathic Membranous Nephropathy
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
The purpose of this study is to provide nephrologists with additional clinical evidence regarding the efficacy and safety of Acthar in subjects with treatment-resistant idiopathic membranous nephropathy.
- Trial name
- CHART (NCT01386554)
- Testing
- Repository Corticotropin Injection
- Where
- 28 sites in United States, Canada and 3 more
- Volunteers
- 60 people
- Sponsor
- Mallinckrodt
Cerebral Atherosclerosis
Clinical Trial of Efficacy and Safety of Divaza for Adjustment of Oxidative Disorders in Patients With Cerebral Atherosclerosis
The purpose of this study is to obtain additional data on efficacy and safety of Divaza for adjustment of oxidative disorders in patients with cerebral atherosclerosis.
- Trial name
- NCT03485495
- Testing
- Divaza
- Where
- 10 sites in Russia
- Volunteers
- 124 people
- Sponsor
- Materia Medica Holding
Influenza, Human
Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU
The main purpose of the this study is to evaluate the safety and tolerability of Immunose™ FLU based on Endocine™ and quadrivalent influenza antigen.
- Trial name
- NCT02998996
- Testing
- 15 µg HA/strain and 1% Endocine™, 15 µg HA/strain and 2% Endocine™, 15 µg HA/strain
- Where
- 2 sites in Sweden
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Eurocine Vaccines AB
Hypercholesterolemia
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia
Primary Objective: To evaluate the effect of alirocumab (SAR236553/REGN727) on low-density lipoprotein cholesterol (LDL-C) levels compared with placebo when co-administered with 80 mg of atorvastatin after 8 weeks of treatment in…
- Trial name
- NCT01288469
- Testing
- Alirocumab, Atorvastatin
- Where
- 20 sites in United States
- Volunteers
- 92 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of JTE-051 administered for 12 weeks in subjects with active rheumatoid arthritis who are receiving background non-biologic disease-modifying…
- Trial name
- MOVE-RA (NCT02919475)
- Testing
- JTE-051
- Where
- 39 sites in United States, Argentina and 8 more
- Volunteers
- 260 people
- Sponsor
- Shionogi Inc.
Eczema, Atopic Dermatitis
Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 5-arm study to assess the effect of Anti-OX40L Monoclonal Antibody (KY1005) in adult participants with moderate to severe atopic…
- Trial name
- STREAM-AD (NCT05131477)
- Testing
- Amlitelimab
- Where
- 103 sites in United States, Australia and 10 more
- Volunteers
- 390 people
- Sponsor
- Kymab Limited
Low Back Pain
A Phase 3 Study of Tanezumab for Chronic Low Back Pain
This study will investigate the efficacy and safety of tanezumab 5 mg and 10 mg administered by subcutaneous injection seven times at 8 week intervals (56 weeks).
- Trial name
- TANGO (NCT02528253)
- Testing
- Tanezumab 5 mg SC, Tanezumab 10 mg SC, Tramadol PR oral
- Where
- 262 sites in United States, Canada and 7 more
- Volunteers
- 1,832 people
- Sponsor
- Pfizer
Hypertension
Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
Evaluate the efficacy (blood pressure lowering effect) and safety of aliskiren alone and in combination with amlodipine in patients with essential hypertension.
- Trial name
- NCT00739973
- Testing
- Aliskiren 150 mg tablet, Aliskiren 300 mg tablet, Amlodipine 5 mg capsule
- Where
- 18 sites in United States, Argentina and 16 more
- Volunteers
- 2,694 people
- Sponsor
- Novartis Pharmaceuticals
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan
- Trial name
- NCT03844945
- Testing
- Netarsudil Ophthalmic Solution 0.01%, Netarsudil Ophthalmic Solution 0.02%, Netarsudil Ophthalmic Solution 0.04%
- Where
- 25 sites in Japan
- Volunteers
- 215 people
- Sponsor
- Aerie Pharmaceuticals
Type 2 Diabetes Mellitus
Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
The primary objective is to demonstrate the superiority of Sotagliflozin 400 milligrams (mg) versus placebo with respect to hemoglobin A1c (Hb1Ac) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic…
- Trial name
- SOTA-BONE (NCT03386344)
- Testing
- Sotagliflozin
- Where
- 53 sites in United States, Australia and 6 more
- Volunteers
- 376 people
- Sponsor
- Lexicon Pharmaceuticals
Genital Herpes
Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients
This study will evaluate the safety and efficacy of single-day famciclovir episodic treatment in Black patients with recurrent genital herpes
- Trial name
- NCT00477334
- Testing
- Famciclovir
- Where
- 43 sites in United States, South Africa
- Volunteers
- 463 people
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.